Antibody Production Market Report 2025 (Global Edition)

Global Antibody Production Market Report 2025 Market Size Split by Product Type (Instruments, Consumables, Software), by Process (Upstream processing, Downstream processing), by Antibody Type (Polyclo...

Antibody Production Market Report Description

We have various report editions of Antibody Production Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Antibody Production Market Insights Video

Competitive Landscape of the Antibody Production Market

The competitive landscape of the antibody production market is dynamic, marked by prominent players driving innovation and market expansion. Key companies focus on strategic collaborations, mergers, and acquisitions to enhance their product portfolios and global presence. Continuous research and development efforts underscore the industry's competitiveness, fostering advancements in bioprocessing technologies and therapeutic applications of antibodies.

Antibody Production Industry News

In February 2023, Thermo Fisher Scientific partnered with Elektrofi for contract manufacturing agreement. This is likely to be operational by early 2024, the partnership aims to establish a current good manufacturing practice (CGMP) line. This strategic move is geared towards bolstering early clinical endeavours across diverse pipeline programs. 

Source-www.elektrofi.com/news/blog-post-title-one-tc9mp#:~:text=The%20collaboration%20with%20Thermo%20Fisher,late%2Dstage%20and%20commercial%20development.

Top Companies Market Share in Antibody Production Industry: (In no particular order of Rank)

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California Inc.
• BGI
• QIAGEN
• Agilent Technologies
• PerkinElmer Inc.
• ProPhase Labs Inc. (Nebula Genomics)
• Psomagen
• Azenta US Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

In terms of revenue, the North America Antibody Production Market share was 40% of the total market

According to Cognitive Market Research, North America dominated the market in 2023 and accounted for around 40% of the global revenue. Robust investments in research and development, coupled with a mature healthcare infrastructure, drive substantial sales. The region benefits from early adoption of advanced bioprocessing technologies and a well-established regulatory framework, fostering innovation and market leadership. Additionally, a high prevalence of chronic diseases fuels the demand for therapeutic antibodies, solidifying North America's position as the leading revenue contributor.

Asia-Pacific is the fastest-growing category. The region's expanding biopharmaceutical industry, coupled with a growing focus on precision medicine, stimulates demand for therapeutic antibodies. Cost-effective manufacturing, a large pool of skilled labour, and increasing outsourcing trends contribute to the region's rapid growth. Favourable regulatory environments, collaborative research initiatives, and a surge in healthcare investments further propel the antibody production market in Asia-Pacific, making it a key player in the global landscape.

The current report Scope analyzes Antibody Production Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Antibody Production

According to Cognitive Market Research, the global antibody production market size was estimated at USD 16421.5 Million out of which North America held the major market of around 40% of the global revenue with a market size of USD 6568.60 million in 2023 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. The region benefits from early adoption of cutting-edge bioprocessing technologies, ensuring efficient antibody production. Robust investments in research and development initiatives by pharmaceutical and biotech giants contribute to market leadership. Moreover, a high prevalence of chronic diseases necessitates therapeutic antibodies, driving substantial sales. Consumables witness increased sales in North America due to a surge in biopharmaceutical activities. Advanced research and a high demand for monoclonal antibodies propel the consumption of essential materials in antibody production.

• According to Cognitive Market Research, the US had a major share in the antibody productions market with a market size of USD 5182.63 million in 2023 and is projected to grow at a CAGR of 11.5% during the forecast period. Sales in antibody production thrive in the U.S. due to robust investments in biotechnology research, fostering innovation. A mature biopharmaceutical sector, coupled with strategic collaborations, propels market growth.
• The Canada antibody productions market had a market share of USD 788.23 million in 2023 and is projected to grow at a CAGR of 12.5% during the forecast period. Canada experiences increased antibody production sales as a result of a growing focus on sustainable bioprocessing practices. Government support, coupled with a skilled workforce, positions the country as a key contributor to the global market.
• The Mexico antibody productions market is projected to witness growth at a CAGR of 12.2% during the forecast period with a market size of USD 597.74 million in 2023.

 

Europe Antibody Production

According to Cognitive Market Research, with a market value of USD 16421.5 million in 2023 and projected to expand at a compound annual growth rate (CAGR) of 12.0% from 2023 to 2030, Europe accounted for a share of around 30% of the global market size of USD 4926.45 million. The region's well-established pharmaceutical industry and extensive healthcare infrastructure create a conducive environment for sales expansion. Increasing government initiatives and funding for biotechnology research contribute to the growth trajectory. A diverse population and rising healthcare awareness drive the demand for targeted antibody therapies, stimulating sales. Collaborations between research institutions and industry players foster innovation, positioning Europe as a key hub for antibody production advancements. In Europe, software dominates the market share with a rising demand for advanced bioprocessing solutions. The region's focus on digitalization and process optimization boosts the adoption of innovative software, ensuring sustained market growth.

• According to Cognitive Market Research, the Germany antibody productions market size was valued at USD 975.44 million in 2023 and is projected to grow at a CAGR of 12.2% during the forecast period. Germany sees a surge in antibody production sales due to its robust pharmaceutical industry and commitment to technological innovation. Research excellence, coupled with efficient bioprocessing, drives market growth.
• The United Kingdom antibody productions market had a market share of USD 827.64 million in 2023 and is projected to grow at a CAGR of 12.8% during the forecast period. In the UK, antibody production sales rise with a strong emphasis on biologics research and development. Collaborations between academia and industry fuel advancements, ensuring a competitive market edge.
• The France antibody productions market is projected to witness growth at a CAGR of 11.2% during the forecast period with a market size of USD 453.23 million in 2023.
• The Italy antibody productions market is projected to witness growth at a CAGR of 11.4% during the forecast period with a market size of USD 423.67 million in 2023.
• The Russia antibody productions market is projected to witness growth at a CAGR of 11.0% during the forecast period with a market size of USD 763.60 million in 2023.
• The Spain antibody productions market is projected to witness growth at a CAGR of 11.1% during the forecast period with a market size of USD 403.97 million in 2023.
• The Portugal antibody productions market is projected to witness growth at a CAGR of 11.8% during the forecast period with a market size of USD 103.46 million in 2023.
• The Luxembourg antibody productions market is projected to witness growth at a CAGR of 12.1% during the forecast period with a market size of USD 152.72 million in 2023.
• The Greece antibody productions market is projected to witness growth at a CAGR of 12.3% during the forecast period with a market size of USD 59.12 million in 2023.
• The Rest of Europe antibody productions market is projected to witness growth at a CAGR of 10.7% during the forecast period with a market size of USD 763.60 million in 2023.

 

Asia Pacific Antibody Production Market

According to Cognitive Market Research, the global antibody production market size was estimated at USD 16421.5 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 3776.95 million in 2023 and will grow at a compound annual growth rate (CAGR) of 15.5% from 2023 to 2030. The region's large pool of skilled labour and lower production costs make it an attractive destination for outsourcing antibody production. Increasing government support and favourable regulatory environments facilitate the expansion of production facilities. The region's dynamic market landscape, characterized by rapid innovation and strategic partnerships, positions it as a major player in the global antibody production market. Downstream processing claims the highest market share in Asia-Pacific, driven by expanding biopharmaceutical endeavours. Increasing purification demands and a focus on therapeutic antibody development contribute to heightened downstream processing sales in the region.

• According to Cognitive Market Research, the China antibody productions market size was valued at USD 1699.63 million in 2023 and is projected to grow at a CAGR of 15.0% during the forecast period. China experiences a significant increase in antibody production sales fuelled by a booming biopharmaceutical sector. Government support, cost-effective manufacturing, and a vast talent pool contribute to market dominance.
• The India antibody productions market had a market share of USD 453.23 million in 2023 and is projected to grow at a CAGR of 17.3% during the forecast period. India witnesses growth in antibody production sales due to its cutting-edge bioprocessing technologies and an aging population. A robust regulatory framework and strategic alliances further enhance the market landscape.
• The Japan antibody productions market is projected to witness growth at a CAGR of 14.0% during the forecast period with a market size of USD 521.22 million in 2023.
• The South Korea antibody productions market is projected to witness growth at a CAGR of 14.6% during the forecast period with a market size of USD 377.69 million in 2023.
• The Australia antibody productions market is projected to witness growth at a CAGR of 15.2% during the forecast period with a market size of USD 196.40 million in 2023.
• The South East Asia antibody productions market is projected to witness growth at a CAGR of 16.5% during the forecast period with a market size of USD 260.61 million in 2023.
• The Rest of Asia Pacific antibody productions market is projected to witness growth at a CAGR of 15.3% during the forecast period with a market size of USD 268.16 million in 2023.

South America Antibody Production

According to Cognitive Market Research, the global antibody productions market size was estimated at USD 16421.5 Million out of which Latin America market of around 5% of the global revenue with a market size of USD 821.08 million in 2023 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2023 to 2030. The region's expanding pharmaceutical sector, coupled with favourable government policies, stimulates investment in antibody research and production facilities. Increasing collaborations with global biopharmaceutical companies bolster technology transfer, contributing to enhanced production capabilities. As Latin America continues to position itself as a key player in the biopharmaceutical arena, sales in antibody production are poised for sustained growth. Monoclonal antibodies lead in Latin America, fuelled by a growing prevalence of diseases. Rising approvals for antibody-based therapeutics and therapeutic advancements contribute to heightened monoclonal antibody sales in the region.

• According to Cognitive Market Research, the Brazil antibody productions market size was valued at USD 351.42 million in 2023 and is projected to grow at a CAGR of 13.5% during the forecast period. Brazil's antibody production sales flourish as a result of a growing biotechnology sector and increasing healthcare investments. Collaborations with global players contribute to technology transfer and market expansion.
• The Argentina antibody productions market had a market share of USD 137.94 million in 2023 and is projected to grow at a CAGR of 13.8% during the forecast period. Argentina sees increased antibody production sales driven by a rising demand for customized therapeutic antibodies. Government initiatives and international collaborations bolster research capabilities, positioning the country as a key market player.
• The Colombia antibody productions market is projected to witness growth at a CAGR of 12.7% during the forecast period with a market size of USD 73.08 million in 2023.
• The Peru antibody productions market is projected to witness growth at a CAGR of 13.1% during the forecast period with a market size of USD 67.33 million in 2023.
• The Chile antibody productions market is projected to witness growth at a CAGR of 13.2% during the forecast period with a market size of USD 59.12 million in 2023.
• The Rest of Latin America antibody productions market is projected to witness growth at a CAGR of 12.0% during the forecast period with a market size of USD 132.19 million in 2023.

 

Middle East Antibody Production

According to Cognitive Market Research, the global antibody production market size was estimated at USD 16421.5 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 328.43 million in 2023 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2023 to 2030. The region's emphasis on research and development initiatives, supported by government funding, propels advancements in antibody production technologies. MEA's commitment to diversifying its economy into knowledge-based industries strengthens its position in the global biopharmaceutical market. As the region establishes itself as a hub for innovation and healthcare development, antibody production sales are poised to grow steadily. Upstream processing dominates in the Middle East and Africa as a result of increasing investments in biotechnology. Advanced cell culture technologies and a surge in research initiatives contribute to elevated upstream processing sales in the region.

• According to Cognitive Market Research, the GCC Countries antibody productions market size was valued at USD 140.57 million in 2023 and is projected to grow at a CAGR of 14.0% during the forecast period. In the GCC Countries, antibody production sales rise due to diversification efforts into biopharmaceuticals. Strategic investments, a favourable regulatory environment, and collaborations foster a flourishing market in the region.
• The South Africa antibody productions market had a market share of USD 51.89 million in 2023 and is projected to grow at a CAGR of 14.2% during the forecast period. South Africa experiences growth in antibody production sales with a focus on combating infectious diseases. Research initiatives, government support, and a developing healthcare infrastructure contribute to a thriving market.
• The Egypt antibody productions market is projected to witness growth at a CAGR of 13.5% during the forecast period with a market size of USD 34.49 million in 2023.
• The Turkey antibody productions market is projected to witness growth at a CAGR of 12.7% during the forecast period with a market size of USD 28.24 million in 2023.
• The Nigeria antibody productions market is projected to witness growth at a CAGR of 12.3% during the forecast period with a market size of USD 34.49 million in 2023.
• The Rest of MEA antibody productions market is projected to witness growth at a CAGR of 12.2% during the forecast period with a market size of USD 38.75 million in 2023.

 

Antibody Production Market Analysis

Antibody Production Market Product Type Segment Analysis

According to Cognitive Market Research, consumables held the major market share over the forecast period. The dominance of consumables in the Antibody Production market is fuelled by continual demand for cell culture media, purification reagents, and chromatography columns. Increasing research activities and therapeutic antibody development drive sustained consumption. Additionally, advancements in disposable technologies enhance scalability, reducing production costs and boosting consumables' market share.

Software is the fastest-growing category over the forecast period. Advanced software solutions streamline process monitoring, optimizing efficiency and reducing errors. Integration of data analytics and artificial intelligence enhances process control, accelerating development timelines. Increasing adoption of sophisticated bioprocess management systems by biopharmaceutical companies contributes to the exponential growth of software in antibody production.

• Instruments
• Consumables
• Software

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Antibody Production Industry. Request a Free Sample PDF!

Antibody Production Market Process Segment Analysis

According to Cognitive Market Research, downstream processing hold a prominent market share. Continuous advancements in chromatography and filtration technologies enhance purification efficiency, meeting stringent regulatory standards. Growing demand for high-quality monoclonal antibodies for therapeutic applications intensifies the utilization of downstream processing. Additionally, the increasing trend of outsourcing production to specialized downstream processing facilities contributes to the segment's significant market share.

Upstream processing is the fastest-growing category over the forecast period. The increasing adoption of single-use bioreactors reduces cross-contamination risks, lowers capital investment, and expedites process development. Robust growth in biopharmaceutical research and a focus on optimizing cell culture conditions further propel upstream processing. The ability to achieve higher cell densities and improved productivity contributes to its status as the fastest-growing segment in antibody production.

• Upstream processing
• Downstream processing

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Antibody Production Antibody Type Segment Analysis

According to Cognitive Market Research, monoclonal antibody hold a prominent market share. Increased approvals for monoclonal antibody-based drugs, especially in cancer and autoimmune treatments, drive robust sales. Ongoing research and development efforts focus on novel monoclonal antibodies, expanding their application areas and solidifying their dominant position in the market.

Polyclonal antibody are the fastest-growing category over the forecast period. Growing demand for diverse antibody responses in diagnostics, coupled with advancements in polyclonal antibody engineering, propels sales. Expanded applications in infectious disease research and diagnostics contribute to the segment's accelerated growth over the forecast period.

• Polyclonal antibody
• Monoclonal antibody

Antibody Production End-Use Segment Analysis

According to Cognitive Market Research, pharmaceutical and biotechnology companies hold a prominent market share due to their substantial investments in research and development. The development and commercialization of antibody-based therapeutics, coupled with a robust pipeline of biologics, contribute to sustained sales. Increasing prevalence of chronic diseases fuels the demand for antibody therapies, solidifying these companies' dominance in the market.

CROs and CDMOs is the fastest-growing category over the forecast period owing to the outsourcing trend in the biopharmaceutical sector. Companies opt for specialized services to streamline production, reduce costs, and expedite development timelines. The flexibility, expertise, and cost-effectiveness offered by CROs and CDMOs attract increased collaborations, driving their accelerated growth in the antibody production market.

• Pharmaceutical and biotechnology companies
• Research laboratories
• CROs and CDMOs

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion